Literature DB >> 9583655

Use of the nicotine skin patch by smokers in 20 communities in the United States, 1992-1993.

K M Cummings1, A Hyland, J K Ockene, N Hymowitz, M Manley.   

Abstract

OBJECTIVE: To measure the characteristics of smokers associated with the use of the nicotine skin patch in the general population and to evaluate whether use of the patch is associated with successful smoking cessation.
DESIGN: Data from two surveys conducted in 20 communities in the United States as part of the National Cancer Institute's Community Intervention Trial for Smoking Cessation (COMMIT) study. Nicotine patch prevalence was estimated using data from a 1993 cross-sectional survey of 13691 current and former smokers. The effectiveness of the nicotine skin patch as a smoking cessation aid was evaluated adjusting for other covariants using data from a cohort tracking study of 9809 smokers who were followed between 1988 and 1993. As the nicotine patch was not available to consumers until January 1992, analyses were restricted to respondents who reported themselves to be current smokers in 1993 or former smokers who reported quitting after January 1992. OUTCOME MEASURES: Current and former smokers who reported having made a serious effort to stop smoking in the past five years were asked to indicate whether they had used the nicotine skin patch to help them stop smoking. Those answering "Yes", were classified as nicotine patch users. Smoking cessation was based on self-report. A "quitter" was defined as someone who had been a smoker as of January 1992 who reported in 1993 not smoking any cigarettes for the preceding six months or longer.
RESULTS: The prevalence of nicotine patch use by smokers averaged across the 20 study communities was 12.8%, making the patch one of the most popular cessation methods used by smokers. Compared with non-users, patch users were more likely to be female, white, have higher annual household incomes, be more motivated to stop smoking, and to smoke more heavily. Among low-income smokers (annual household income below US$10000), nicotine patch use was significantly higher among those who lived in a state where the public insurance programme (Medicaid or Medi-Cal) included the patch as a benefit (12.1% vs 7.7%). Among those who made an attempt to quit smoking, the likelihood of successful quitting was more than twice as high among patch users compared with non-users. Among patch users, the highest quit rates were observed among those who used the patch for between one and three months.
CONCLUSIONS: The nicotine skin patch is a popular and effective means of smoking cessation. Use of the nicotine patch, especially by low-income smokers, could be increased by reducing the out-of-pocket expenditure required for smokers to get the product.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9583655      PMCID: PMC1766211          DOI: 10.1136/tc.6.suppl_2.s63

Source DB:  PubMed          Journal:  Tob Control        ISSN: 0964-4563            Impact factor:   7.552


  15 in total

1.  Effect on smoking cessation of switching nicotine replacement therapy to over-the-counter status.

Authors:  Anne N Thorndike; Lois Biener; Nancy A Rigotti
Journal:  Am J Public Health       Date:  2002-03       Impact factor: 9.308

2.  The uninsured and Medicaid Oregon tobacco user experience in a real world, phone based cessation programme.

Authors:  Ay El-Bastawissi; T McAfee; S M Zbikowski; J Hollis; M Stark; K Wassum; N Clark; R Barwinski; E Broughton
Journal:  Tob Control       Date:  2003-03       Impact factor: 7.552

Review 3.  Multilevel interventions and racial/ethnic health disparities.

Authors:  Sherri Sheinfeld Gorin; Hoda Badr; Paul Krebs; Irene Prabhu Das
Journal:  J Natl Cancer Inst Monogr       Date:  2012-05

4.  Characteristics of selectors of nicotine replacement therapy.

Authors:  S Shiffman; M E Di Marino; C T Sweeney
Journal:  Tob Control       Date:  2005-10       Impact factor: 7.552

5.  Early quit days among methadone-maintained smokers in a smoking cessation trial.

Authors:  Marcel A de Dios; Bradley J Anderson; Celeste M Caviness; Michael D Stein
Journal:  Nicotine Tob Res       Date:  2014-06-20       Impact factor: 4.244

Review 6.  Effectiveness of over-the-counter nicotine replacement therapy: a qualitative review of nonrandomized trials.

Authors:  John R Hughes; Erica N Peters; Shelly Naud
Journal:  Nicotine Tob Res       Date:  2011-04-06       Impact factor: 4.244

7.  Changes in cigarette consumption and drinking outcomes: findings from Project MATCH.

Authors:  Karen B Friend; Maria E Pagano
Journal:  J Subst Abuse Treat       Date:  2005-10

8.  An Open Trial of Electronic Cigarettes for Smoking Cessation Among Methadone-Maintained Smokers.

Authors:  Michael D Stein; Celeste Caviness; Kristin Grimone; Daniel Audet; Bradley J Anderson; Genie L Bailey
Journal:  Nicotine Tob Res       Date:  2015-12-28       Impact factor: 4.244

9.  Varenicline for smoking cessation among methadone-maintained smokers: a randomized clinical trial.

Authors:  M D Stein; C M Caviness; M E Kurth; D Audet; J Olson; B J Anderson
Journal:  Drug Alcohol Depend       Date:  2013-08-14       Impact factor: 4.492

10.  Low incidence of adverse events following varenicline initiation among opioid dependent smokers with comorbid psychiatric illness.

Authors:  Shadi Nahvi; Bryan Wu; Kimber P Richter; Steven L Bernstein; Julia H Arnsten
Journal:  Drug Alcohol Depend       Date:  2013-01-17       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.